Physician profile
Sarada Uppuluri
NPI 1477679694
$1,982.12
in general payments reported to CMS, 2019-2025
22 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $97.30 · 2021: $125 · 2022: $216 · 2023: $195 · 2024: $455 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $526.89 | 2019-2025 | Sapien 3 Ultra Resilia, Evoque |
| Pfizer INC. | $357.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $253.27 | 2019-2025 | Brilinta, Farxiga |
| Boston Scientific Corporation | $211.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $136.23 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $68.04 | 2019-2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $65.86 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $58.84 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $44.04 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $33.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.31 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.85 | 2023-2024 | Jardiance |
| Heartflow, INC. | $28.29 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.94 | 2023 | |
| Medtronic, INC. | $16.55 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $15.66 | 2024 | |
| Vifor Pharma, INC. | $15.52 | 2019 | |
| Chiesi USA, INC. | $14.92 | 2025 | Cleviprex, Kengreal |
| Amarin Pharma, INC. | $14.69 | 2020 | |
| Amgen INC. | $14.50 | 2019 | |
| Merck Sharp & Dohme LLC | $13.79 | 2024 | Verquvo |
| Medtronic Vascular, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarada Uppuluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.